Literature DB >> 34470774

Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia.

Abhishek Maiti1, Naval G Daver2.   

Abstract

Cellular therapies have demonstrated limited efficacy thus far in acute myeloid leukemia (AML). A recent study shows that mTOR complex 1 activation downregulated CXCR4 reducing marrow infiltration of EpCAM-targeting chimeric antigen receptor (CAR) T-cells in AML. Abrogating mTOR signaling by cotreatment with mTOR inhibitors during IL2-mediated ex vivo expansion upregulated CXCR4 and bolstered bone marrow migration and AML elimination by CAR T-cells.See related article by Nian et al., p. 6026. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34470774      PMCID： PMC8563411          DOI： 10.1158/1078-0432.CCR-21-2574

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.

Authors:  Naval Daver; Ahmad S Alotaibi; Veit Bücklein; Marion Subklewe
Journal:  Leukemia       Date:  2021-05-05       Impact factor: 11.528

Review 2.  Engineering strategies to overcome the current roadblocks in CAR T cell therapy.

Authors:  Sarwish Rafiq; Christopher S Hackett; Renier J Brentjens
Journal:  Nat Rev Clin Oncol       Date:  2019-12-17       Impact factor: 65.011

3.  Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X.

Authors:  Emily Levy; Robert Reger; Filip Segerberg; Melanie Lambert; Caroline Leijonhufvud; Yvonne Baumer; Mattias Carlsten; Richard Childs
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

Review 4.  Counteracting CAR T cell dysfunction.

Authors:  Mansour Poorebrahim; Jeroen Melief; Yago Pico de Coaña; Stina L Wickström; Angel Cid-Arregui; Rolf Kiessling
Journal:  Oncogene       Date:  2021-01-14       Impact factor: 9.867

5.  Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells.

Authors:  Zhigang Nian; Xiaohu Zheng; Yingchao Dou; Xianghui Du; Li Zhou; Binqing Fu; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Clin Cancer Res       Date:  2021-07-07       Impact factor: 12.531
  5 in total
  1 in total

Review 1.  From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.

Authors:  Jiangang Sun; Xiaojing Li; Peng Chen; Yongshun Gao
Journal:  J Inflamm Res       Date:  2022-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.